Francis Kynaston-Pearson: Why Randomised Controlled Trials Are the Gold Standard in Clinical Research
Francis Kynaston-Pearson, Consultant Rheumatologist at Mediclinic Middle East, shared a post on LinkedIn:
“The randomised control trial (RCT) – the ‘gold standard’ for clinical evidence.
If that is so, why is all evidence not gathered in such a manner.
For those in research, the answer is evident but doctors and scientists forget that the complexities of the nuts and bolts of a quality trial are not common knowledge of our patients.
Not all questions can be answered with an RCT, not to mention the cost in setting one up.
Trials with mild or moderate methodological failing or negative results may not even get published, with the hard work never known outside the investigating team.
For anyone who wanted a quick overview of RCTs but was a little afraid or embarrassed to ask, here is a quick video for you.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention